Verdence Capital Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.76M | Buy |
26,461
+1,340
| +5% | +$297K | 0.33% | 63 |
|
|
2025
Q4 | $5.74M | Sell |
25,121
-1,343
| -5% | -$306K | 0.34% | 65 |
|
|
2025
Q3 | $6.03M | Sell |
26,464
-853
| -3% | -$174K | 0.35% | 64 |
|
|
2025
Q2 | $5.07M | Buy |
27,317
+1,099
| +4% | +$204K | 0.35% | 68 |
|
|
2025
Q1 | $5.49M | Buy |
26,218
+765
| +3% | +$149K | 0.42% | 57 |
|
|
2024
Q4 | $4.52M | Buy |
25,453
+3,127
| +14% | +$575K | 0.36% | 63 |
|
|
2024
Q3 | $4.41M | Buy |
22,326
+1,164
| +6% | +$217K | 0.35% | 66 |
|
|
2024
Q2 | $3.63M | Buy |
21,162
+718
| +4% | +$119K | 0.32% | 72 |
|
|
2024
Q1 | $3.72M | Sell |
20,444
-2,630
| -11% | -$453K | 0.34% | 71 |
|
|
2023
Q4 | $3.58M | Buy |
23,074
+1,051
| +5% | +$153K | 0.35% | 71 |
|
|
2023
Q3 | $3.28M | Buy |
22,023
+3,621
| +20% | +$532K | 0.36% | 69 |
|
|
2023
Q2 | $2.48M | Sell |
18,402
-1,261
| -6% | -$185K | 0.29% | 96 |
|
|
2023
Q1 | $3.13M | Sell |
19,663
-5,963
| -23% | -$912K | 0.38% | 67 |
|
|
2022
Q4 | $4.14M | Sell |
25,626
-373
| -1% | -$57.2K | 0.51% | 42 |
|
|
2022
Q3 | $3.49M | Buy |
25,999
+834
| +3% | +$120K | 0.48% | 51 |
|
|
2022
Q2 | $3.85M | Sell |
25,165
-14,628
| -37% | -$2.24M | 0.5% | 46 |
|
|
2022
Q1 | $6.45M | Buy |
39,793
+1,095
| +3% | +$159K | 0.73% | 30 |
|
|
2021
Q4 | $5.24M | Buy |
38,698
+419
| +1% | +$49.5K | 0.62% | 41 |
|
|
2021
Q3 | $4.13M | Buy |
38,279
+192
| +0.5% | +$21.9K | 0.54% | 44 |
|
|
2021
Q2 | $4.29M | Buy |
38,087
+731
| +2% | +$82.3K | 0.6% | 37 |
|
|
2021
Q1 | $4.04M | Sell |
37,356
-376
| -1% | -$40.2K | 0.68% | 31 |
|
|
2020
Q4 | $4.04M | Buy |
37,732
+116
| +0.3% | +$11.1K | 0.77% | 28 |
|
|
2020
Q3 | $3.29M | Sell |
37,616
-2,619
| -7% | -$247K | 0.76% | 30 |
|
|
2020
Q2 | $3.95M | Sell |
40,235
-3,144
| -7% | -$277K | 0.97% | 24 |
|
|
2020
Q1 | $3.31M | Buy |
43,379
+4,671
| +12% | +$398K | 0.99% | 22 |
|
|
2019
Q4 | $3.43M | Sell |
38,708
-525
| -1% | -$43.6K | 0.84% | 29 |
|
|
2019
Q3 | $2.97M | Buy |
39,233
+4,348
| +12% | +$298K | 0.83% | 30 |
|
|
2019
Q2 | $2.54M | Sell |
34,885
-2,227
| -6% | -$175K | 0.73% | 36 |
|
|
2019
Q1 | $2.99M | Buy |
37,112
+4,984
| +16% | +$408K | 0.81% | 39 |
|
|
2018
Q4 | $2.96M | Buy |
32,128
+8,640
| +37% | +$760K | 0.83% | 33 |
|
|
2018
Q3 | $2.22M | Buy |
23,488
+1,021
| +5% | +$96.8K | 0.55% | 48 |
|
|
2018
Q2 | $2.08M | Sell |
22,467
-11
| -0% | -$1.07K | 0.51% | 54 |
|
|
2018
Q1 | $2.13M | Sell |
22,478
-8,525
| -27% | -$936K | 0.51% | 51 |
|
|
2017
Q4 | $3M | Buy |
+31,003
| New | +$2.92M | 0.71% | 40 |
|
Other funds holding ABBV
VCM
VPM
Verdence Capital Advisors's ABBV Position: Q1 2026 in Review
Verdence Capital Advisors increased its AbbVie (ABBV) stake by 5.3% in Q1 2026, buying an estimated $297K and bringing the position to 26,461 shares worth $5.76M. The position accounts for 0.33% of the portfolio, ranked #63.
Verdence Capital Advisors first reported a position in ABBV in Q4 2017 and has held it in 34 quarters since. The position peaked at $6.45M in Q1 2022. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Verdence Capital Advisors held 26,461 shares of AbbVie worth $5.76M as of Q1 2026.
- Verdence Capital Advisors bought 1,340 AbbVie shares in Q1 2026, an estimated $297K.
- AbbVie made up 0.33% of Verdence Capital Advisors's portfolio in Q1 2026, its #63 holding.
- Verdence Capital Advisors first reported a position in AbbVie in Q4 2017 and has held it in 34 quarters since.
- Verdence Capital Advisors's AbbVie position peaked at $6.45M in Q1 2022.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Verdence Capital Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.